Pharmacodiagnostic Testing in Breast Cancer: Focus on HER2 and Trastuzumab Therapy

Author： Bartlett John M.S.  

Publisher： Adis International

ISSN： 1175-2203

Source： American Journal of PharmacoGenomics, Vol.5, Iss.5, 2005-01, pp. : 303-315

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer

By  

Current Cancer Drug Targets, Vol. 9, Iss. 2, 2009-03 ,pp. : 148-162

Bentham Science Publishers

Access to resources Recommend Favorite

Trastuzumab tallies up in HER2+ breast cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 541, 2007-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Trastuzumab tallies up in HER2+ breast cancer

By  

Inpharma, Vol. 1, Iss. 1614, 2007-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy

By  

Current Cancer Drug Targets, Vol. 17, Iss. 4, 2017-04 ,pp. : 344-356

Bentham Science Publishers

Access to resources Recommend Favorite

Neoadjuvant docetaxel, vinorelbine and trastuzumab prior to surgery and adjuvant therapy is active in patients with HER-2 breast cancer

By  

Inpharma, Vol. 1, Iss. 1579, 2007-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite